Cempra (CEMP) Tops Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Baird Remains Bullish Following Cempra's (CEMP) 4Q; Focus Remains on Solithromycin Launch
February 25, 2016 7:09 AM ESTBaird maintained an Outperform rating on Cempra, Inc. (NASDAQ: CEMP), and cut the price target to $33.00 (from $38.00), following the company's 4Q. Cempra is currently focused on completing regulatory submissions for Solithromycin in CABP and prepping for launch in 2017. As such, the company's 4Q results are... More
